Bevacizumab [BEV8]

The third line treatment of low grade gliomas of childhood where all the following criteria are met:

  1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant paediatric specialist specifically trained and accredited in the use of systemic anti-cancer therapy
  2. Progressive low grade glioma
  3. No previous treatment with either irinotecan or bevacizumab
  4. Irinotecan and bevacizumab to be the 3rd or further line of therapy
  5. A maximum of 12 months duration of treatment to be used
  6. Consent with the parent/guardian to specifically document the unknown long term toxicity of this combination, particularly on growth and ovarian function
  7. To be used within the treating Trust’s governance framework, as Bevacizumab and Irinotecan are not licensed in this indication in children
  8. In the period immediately prior to the application for irinotecan and bevacizumab, the appropriate specialist MDT has considered the use of proton beam radiotherapy. NOTE: Bevacizumab is ONLY approved for use in combination with combination chemotherapy and is not approved for use as a single agent maintenance therapy NOTE: Additional data on long term toxicity must be collected by the paediatric oncology community

[NHS funded]{.badge .rounded-pill .bg-success} From: 01 April 2021

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: - NHS England clinical policy (NA)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.